Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, Phase 2a, randomized, double-blind, placebo-controlled pilot study to
assess the biological activity, safety and pharmacokinetics of PU-AD compared to placebo in
ALS. It will be conducted in approximately 20 sites in the US. Approximately 30 subjects will
be enrolled in this study; subjects will be randomized 3:2 to receive either PU-AD 30 mg or
matching placebo qd, added onto any current stable background treatment.